Health and Healthcare
1490 Articles
One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night…
One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have…
thinkstockDecember 26, 2014: Markets opened higher on Friday on a morning when it was difficult to find any market-moving news…
With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow…
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…
thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains…
The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good…
A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference…
thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second…
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.
thinkstockOctober 24, 2014: Markets opened slightly higher on Friday, and following a short trip below the break-even line, marched higher…
Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."
thinkstockOctober 16, 2014: Markets opened lower on Thursday following a sharp drop in crude oil prices overnight and a better-than-expected…
Short sellers have decided to get out of some of the go-to defensive stocks with high-dividend yields in late September.
Our top personal finance-related articles today. Your wallet will thank you later.